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1. Introduction  
According to the World Health Organization (WHO), by 2020 depression is expected to rise to 
the number two contributor to global burden of disease (WHO, 2005). However according to 
recent reports, depression comprises the most costly brain disorder in Europe, accounting 
for 33% of the total cost that corresponds to about 1% of the European gross domestic 
product (GDP) (Sobocki et al., 2006). Despite the fact that our knowledge regarding the 
pathophysiology and the neurobiological substrate of depression has grown exponentially 
over the last decades, there is still a significant percentage of patients who respond poorly or 
do not tolerate current antidepressant pharmacotherapies (Rush, 2007). Most likely, the 
latter reflects the fact that the term “depression” encompasses a group of disorders, with 
each being characterized by a unique endophenotype that deserves tailor-made treatment 
strategies (Hasler et al., 2004; Antonijevic, 2006). 
Major depression is a leading cause of disability among women 15-44 years and twice as 
many women as men suffer from this debilitating condition annually (Kessler et al., 1994; 
Young et al., 2009). Paradoxically, research regarding the neurobiological substrate of 
depressive disorders, as well as response to antidepressant medications has focused 
almost exclusively on the male sex. However, as noted in a recent review, evidence exist 
that genetic variations in loci related to central neurotransmitter and neuromodulatory 
systems, may be implicated in the sex-differentiated manifestation of depressive 
symptomatology and differential responsiveness to various antidepressant drugs 
(Pitychoutis et al., 2010a).    
The selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) comprise 
the most widely prescribed class of antidepressants worldwide. However, they present with 
variable therapeutic efficacy, which is often accompanied by numerous side-effects. Most 
importantly, the protracted period of time (3-4 weeks) in order for these agents to induce a 
clinically meaningful improvement in depressive symptomatology has been associated with 
increased drop-out rates. Not surprisingly, only 60-65% of adult depressed patients respond 
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to the first course of therapy and among responders less than half either reach remission or 
become free of symptoms (Rosenzweig-Lipson et al., 2007). Thus, the need for more effective 
pharmacotherapies to combat depression is an ever-growing concern due to the enormous 
societal and financial ramifications of these disorders.  
The present chapter focuses on current advances in the field of pharmacogenetics of major 
depression under the prism of sex differences. In order to treat depression, a personalized 
approach including better-targeted therapies may be needed. Understanding sex differences 
in response to antidepressant medications is a major step towards this direction. 
2. Sex differences in major depression  
Major depression occurs more frequently in women than in men. Despite the fact that the 
aetiology behind this sex difference is still elusive, scientists agree that it possibly reflects 
a complex genetic, hormonal, biochemical and social interplay. Prior to puberty, no 
significant differences are detected regarding the precipitation of depressive 
symptomatology between the male and the female sex (Kuehner, 2003), whereas during 
the reproductive period women appear to experience major depression at roughly twice 
the rate of men (Marcus et al., 2005; Grigoriadis & Robinson, 2007; Pitychoutis & 
Papadopoulou-Daifoti, 2010). Of note, an increasing amount of data suggests that 
associations between stressful interpersonal events and depression are stronger in women 
than in men (Oldehinkel & Bouma, 2011).  
Interestingly, in depression, a sex-specific symptom pattern may occur. According to some 
reports men seem to lose more weight while women tend to report more appetite and 
weight increase, accompanied by hypochondriasis and somatic concerns (Young et al., 1990; 
Kornstein et al., 2000b). More recently, Marcus et al. (2005) analyzed data from the STAR*D 
(Sequenced Treatment Alternatives to Relieve Depression) multicenter trial; in this sample 
women reported an earlier onset of the first major depressive episode, as well as a trend 
towards a greater length of the current episode. In the same study, alcohol and drug 
dependence were more common in men. Importantly, even though women reported greater 
likelihood of having attempted a suicide in the past, men were characterized by greater 
psychomotor agitation and suicidal ideation (Marcus et al., 2005).   
Even though these statistics have been partly attributed to the fact that women are more 
likely to seek psychiatric assistance in view of a negative affective status and to be over-
diagnosed with major depression compared to men (Grigoriadis & Robinson, 2007), 
nowadays there is enough evidence for sex-differentiated biological pathways in affective 
disorders. Notably, a variety of serotonergic sexual dimorphisms have been hypothesized to 
confer increased vulnerability of females to depression. In this context, whole brain 5-HT 
synthesis and 5-HT2 receptor binding have been reported to be lower in several regions of 
the female brain (for review see Rubinow et al., 1998). 
3. Sex differences in antidepressant response: Insights from the clinic and 
from animal models of depression 
Converging albeit inconclusive evidence support the existence of a sex-differentiated 
responsiveness to antidepressant drugs (Dalla et al., 2011; Sloan & Kornstein, 2003; Marcus et 
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al., 2005). Indeed, earlier studies reported that women presented a slower response to 
tricyclic antidepressants (TCAs) (Prange et al., 1969), while also being less likely to achieve 
remission (Glassman et al., 1977). In an intriguing study conducted in a sample of 235 male 
and 400 female depressed outpatients, women were more likely to show a favourable 
response to the SSRI sertraline than to the TCA imipramine, while the opposite association 
seemed to hold true for men (Kornstein et al., 2000a). This sex-differentiated interplay was 
also accompanied by a sex-based adverse effect profile; while depressed men treated with 
imipramine reported sexual dysfunction, urinary frequency and dyspepsia at a higher 
percentage, depressed women treated with sertraline complained more frequently about 
nausea and dizziness (Kornstein et al., 2000a). The STAR*D is the largest study of major 
depression ever conducted in the US and the largest to address sex differences in 
prospective treatment using a representative sample of 2,876 treatment-seeking depressed 
patients (Rush et al., 2004; Young et al., 2009). Using data from this study, Young et al. (2009)  
reported that women that received the SSRI citalopram for 12-14 weeks presented 33% 
greater likelihood of remission as compared to male depressed patients (Young et al., 2009). 
Importantly, this sex difference was attributed to sex-specific biological differences in the 
serotonergic system (Young et al., 2009). However, it should be noted that other studies have 
not detected sex-related effects of antidepressants in humans. For instance, Quitkin et al. 
(2002) found no significant difference in response to the SSRI fluoxetine in a sample of 840 
outpatients. In another study, Thiels et al. (2005) did not report a significant difference in 
response to 6-month treatment with the SSRI sertraline. Therefore, the clinical significance of 
these findings still remains controversial (Quitkin et al., 2002; Hildebrandt et al., 2003; Thiels 
et al., 2005).  
Sex differences in response to antidepressant pharmacotherapy have been largely attributed 
to the sex-differentiated pharmacokinetic disposition of psychotropic agents. Studies in 
humans and in laboratory animals have shown that females are characterized by increased 
levels of hepatic cytochrome P450 (CYP) 3A. Thus, it has been suggested that over-
expression of CYP3A, may modulate the effectiveness of drugs in women (Paine et al., 2005; 
Waxman & Holloway, 2009). Moreover, the estrogen-altering oral contraceptives and 
hormonal replacement therapies may ultimately influence the pharmacokinetic disposition 
of antidepressants (Yonkers et al., 1992; Hildebrandt et al., 2003). Despite the fact that 
available pharmacokinetic evidence indicates that women should perhaps receive lower 
doses of antidepressants as compared to men, current guidelines do not suggest that men 
and women should be dosed in a sex-based manner (Kokras et al., 2011).  
The clinical finding of a sex-differentiated antidepressant response has also been validated 
in preclinical research (Dalla et al., 2010; 2011). For instance, in a most recent study we 
reported that male rats may benefit to a greater extent when treated chronically with the 
TCA clomipramine (Pitychoutis et al. 2011). We further revealed that individual differences 
in response to novelty may predict differential responsiveness to clomipramine treatment 
and are associated with qualitative and quantitative sex-related behavioral and 
neurochemical alterations (Pitychoutis et al. 2011). Further, clomipramine treatment may 
induce sex-differentiated effects on cellular immunoreactivity in the chronic mild stress 
(CMS) model of depression, with female rats presenting a relatively immunosuppressed 
phenotype as compared to males (Pitychoutis et al., 2009; Pitychoutis et al., 2010b). 
Moreover, 2 weeks of clomipramine treatment in the Flinders Sensitive Line (FSL) rats, a 
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putative genetic model of depression, induced sex-related effects on behavioral despair, as 
assessed in the forced swim test (FST), that were accompanied by sexually dimorphic 
serotonergic alterations in several limbic brain regions (Kokras et al., 2009).  
4. Sex differences in the pharmacogenetics of antidepressants 
Pharmacogenetics investigates how genes influence responsiveness to drugs, both in terms 
of efficacy and adverse effects. The ultimate goal of this scientific field is to provide “tailor-
made” pharmacotherapies based on the genetic constitution of the individual. Importantly, 
genetic prediction of antidepressant response has the potential to facilitate an informed 
choice of agent and a patient-tailored dose in order for response rates to be significantly 
improved and adverse effects to be alleviated.  
Recent pharmacogenetic research on the impact of sex on antidepressant treatment has 
focused mostly on SSRIs, because these drugs represent the first-choice of pharmacological 
intervention for the treatment of major depression worldwide. Given that not all patients 
respond sufficiently to the initial treatment with an SSRI, non-response has been associated 
with individual differences in pharmacodynamic processes and in this context has been 
partly attributed to the polymorphic nature of certain genes related to the metabolism of 
monoamines, to the serotonergic and other neurobiological systems (Steimer et al., 2001). 
Multiple genes influencing central monoaminergic neurotransmission have served as targets 
of vast pharmacogenetic screening. Among these are the rate-limiting enzyme of 5-HT 
biosynthesis, tryptophan hydroxylase 1 & 2 (TPH1 & TPH2), inactivation enzymes 
monoamine oxidases A & B (MAO-A; MAO-B) and catechol-O-methyl-transferase (COMT), 
as well as 5-HT’s protein-targets, such as the 5-HT1A receptor (Drago et al., 2009). In humans, 
there are two distinct TPH genes located on chromosomes 11 and 12, coding for two 
different homologous enzymes, with TPH2 being the predominant isoform in the CNS 
(Walther & Bader, 2003).  
Therefore, sedulous research on whether/which DNA polymorphisms are somehow 
involved in SSRI responsiveness and if these vary between the two sexes, is of great 
importance for improving the clinical care of depressed patients. 
4.1 Genes related to the metabolism of monoamines 
Three monoamine-related genes have been associated to date with a sex-dependent 
antidepressant response (Table 1). The MAO-A gene is located on the X chromosome in 
humans, is expressed on the outer mitochondrial membrane where it catabolizes the 
intraneuronal deamination of dopamine (DA), norepinephrine (NA), and 5-HT. A prominent 
variable number tandem repeat (VNTR) polymorphism consists of a 30 base pair repeated 
sequence present in 2, 3, 3.5, 4, or 5 repeats (R) at 1.2 kb upstream of the MAO-A gene and 
affects its enzymatic activity. Specifically, the 3.5R and 4R alleles transcribe 2–10 times more 
efficiently as compared to 2, 3, or 5R alleles (Muller et al., 2002; Drago et al., 2009). This 
polymorphism has been associated with the response rates of depressed women to the SSRI 
fluoxetine in a Chinese patient cohort. According to this study, women carriers of the shorter 
3R-allele (low-transcribers of the MAO-A gene) responded better to 4-week fluoxetine 
treatment as compared to the longer 4R-allele carriers (high-transcribers of the MAO-A gene) 
(Yu et al., 2005). Notably, no such association was observed among the male population 
included in this study. Similar findings were observed in a cohort of Caucasian depressed 
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patients, who were treated with various antidepressant drugs (Domschke et al., 2008b). Again, 
the longer MAO-A alleles were associated with a greater risk of slower and less efficient 
response in a sex-specific context (i.e. in female patients only). Noteworthy, other studies have 
failed to detect any effect of this variant on pharmacoresponse in major depression (Cusin et 
al., 2002; Muller et al., 2002; Peters et al., 2004). A second MAO-A polymorphism (T941G) has 
been reported to affect treatment response to mirtazapine in a sex-specific manner. 
Mirtazapine-treated depressed women homozygous for the T-allele showed a faster and better 
response compared to patients carrying the TG or GG genotype, while in men no association 
was observed (Tadic et al., 2007a). Another study provided evidence regarding the implication 
of the functional A644G SNP within intron 13 of the MAO-B gene, in the outcome of treatment 
with paroxetine only in women with major depression (Tadic et al., 2007b). The 
aforementioned associations may not be unrelated to the fact that the genes encoding MAO-A 
and MAO-B are located on the short arm of the X chromosome (Yu et al., 2005). 
 
 
GENE 
GENETIC 
VARIATION 
DRUG RESULT REFERENCE 
MAO-A 
30 bp VNTR 
(promoter) 
fluoxetine 
Women with the "shorter" 
3R/3R genotype responded 
better to fluoxetine treatment 
as compared to those with the 
"longer" 4R allele 
Yu et al., 2005 
MAO-A 
30 bp VNTR 
(promoter) 
mirtazapine, 
citalopram/ 
escitalopram, 
venlafaxine 
and 
combinations 
In women, the "longer" alleles 
were associated with slower 
and less efficient response to 
antidepressant treatment 
Domschke et al., 
2008b 
MAO-A 
T941G 
(synonymous; 
Arg297) 
mirtazapine or 
paroxetine 
Women homozygous for 
the T-allele presented faster 
and 
better response to 
antidepressant treatment as 
compared to TG/GG-patients 
Tadić et al., 
2007a 
MAO-B 
A644G (intron 
13) 
mirtazapine or 
paroxetine 
Women homozygous for the A-
allele showed a clinically 
meaningful faster and more 
pronounced response to 
treatment with paroxetine  
Tadić et al., 
2007b 
COMT 
G472A 
(Val158Met) 
fluoxetine 
In men, the Val/Val genotype 
was associated with poorer 
response to antidepressant 
treatment  
Tsai et al., 2009 
Table 1. Sex differences in genetic variants implicated in the metabolism of monoamines. 
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Depressive symptomatology can be alleviated by SSRI treatment, partly due to the 
enhancement of the serotonergic tone that in turn enhances dopamine outflow in the reward 
system of the brain (Naranjo et al., 2001). Given that the COMT enzyme degrades DA, it 
represents a promising candidate for pharmacogenetics screening. A functional SNP 
(G472A) that causes a substitution of Valine to Methionine in codon 158 (Val158Met) of the 
COMT gene results in a three- to four-fold decrement of the enzymatic activity of the 
membrane-bound isoform (Lachman et al., 1996). Notably, a recent study by Tsai and 
colleagues (2009) conducted in Chinese depressed patients treated with fluoxetine revealed 
a sex-dependent association of the COMTVal/Val genotype with poorer antidepressant 
response, but only in male patients (Tsai et al., 2009). 
4.2 Genes specific to serotonergic neurotransmission 
A battery of pharmacogenetic studies have focused on genetic variations of the 5-HT 
transporter (SLC6A4; 5-HTT) gene that is located on chromosome 17 in humans (Table 2; 
Drago et al., 2009). Perhaps the most interesting is the functional polymorphism on the 
promoter of the 5-HTT gene, known as 5-HTT gene-linked polymorphic region (5-HTTLPR) 
that consists of 16 imperfect 22 base pair repeats. The polymorphic nature of this site regards 
the relative presence/absence of two of the repeats. Thus, their absence produces a shorter 
allele (S), whereas their presence produces a 44 base-pair longer allele (L). According to this 
“bi-allelic scheme”, carriers of the L-allele are characterized by an enhanced expression rate of 
the 5-HTT, with the opposite holding true for the carriers of the S-allele. Most importantly, it 
has been hypothesized that L-allele carriers may benefit to a greater extent from 
antidepressant treatment. This notion has been attributed to a generalized responsiveness of 
the serotonergic system owing to the enhanced expression/activity of 5-HTT (Serretti et al., 
2007). Notably, the 5-HT1A receptor transcription rate is modulated by a variation (C1019G) 
in the upstream regulatory region of this gene. Indeed, the C-allele appears to be associated 
with the down-regulation of 5-HT1A receptor that may explain the better response rates to 
chronic antidepressant treatment (Parsey et al., 2006; Drago et al., 2009).  
A recent study by Smits et al. (2008) screened the 5-HTTLPR polymorphism of the 5-HTT 
gene for associations with non-responsiveness to SSRI treatment (Smits et al., 2008). 
According to these results, the response of male patients of a Caucasian cohort to SSRI 
treatment was independent of the studied polymorphisms in the 5-HTT locus, whereas in 
women the 5-HTLPR S-allele was associated with a less favorable response to treatment. 
These findings replicated in part an earlier study showing that paroxetine efficacy in 
patients with panic disorder was lower in women with the SS genotype compared to 
women carrying the L-allele (Perna et al., 2005). Another  study lent further support and 
extended the aforementioned associations; in depressed patients 4-week treatment with 
either SSRIs or non-SSRI drugs, the S-allele was associated with lower antidepressant 
efficacy in depressed women but not in men, with this result being significant for both types 
of medication (Gressier et al., 2009). Importantly, in a follow-up study the same group 
reported that depressed women with the SS genotype responded poorly to antidepressant 
treatment as compared to women with LL/LS genotype, whereas no significant difference 
was detected in men (Gressier et al. 2011). Moreover, in the same study, the S-allele was 
associated with elevated concentrations of thyroid stimulating hormone (TSH) levels in 
depressed women, thus underlining the important interaction among sex, thyroid function 
and the serotonergic system (Gressier et al. 2011) 
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A study by Yu et al. (2006) further supported the impact of sex in the prediction of the 
effectiveness of SSRI treatment (Yu et al., 2006). These authors reported that the C/C 
genotype of the C1019G polymorphism of the 5-HT1A receptor gene may be considered a 
sex-specific factor for the prediction of a beneficial outcome with fluoxetine treatment, only 
in female patients of a Chinese cohort. 
 
GENE 
GENETIC 
VARIATION 
DRUG RESULT REFERENCE 
5-HTT 
5-HTTLPR 
(promoter) 
SSRIs; paroxetine 
the most 
frequently 
prescribed 
Women with the S-allele 
showed a less favourable 
response to SSRI treatment 
Smits et al., 2008 
5-HTT 
5-HTTLPR 
(promoter) 
SSRIs and non-
SSRIs 
The SS genotype was 
associated with lower 
antidepressant efficacy 
with both SSRI and non-
SSRI drugs in depressed 
women but not in men 
Gressier et al., 
2009 
5-HT1A 
C1019G 
(promoter)  
fluoxetine 
Women with the C/C 
genotype showed a better 
response than G-allele 
carriers 
Yu et al., 2006 
Table 2. Sex differences in genetic variants that are specific to the serotonergic system. 
4.3 Genes related to other neurobiological systems 
Genetic variants associated with other neurobiological systems have also been implicated in 
patients’ response to antidepressant agents (Table 3). For instance, the angiotensin I 
converting enzyme (ACE) gene is expressed in the brain where it degrades several 
neuropeptides, such as substance P (Skidgel & Erdos, 1987). The latter, has been strongly 
implicated in the neurobiology of major depression, while antagonists for this neuropeptide 
have been reported to significantly improve depressive symptoms (Kramer et al., 1998; Nutt, 
1998). Research on an insertion/deletion (I/D) polymorphism, represented by the 
presence/absence of a 287 base pair region within the ACE gene has indicated that the D-
allele was associated with faster onset of antidepressant therapy (i.e. SSRIs, TCAs etc), but 
only in female depressed patients (Baghai et al., 2004).  
Preclinical research in animal models implicates the endocannabinoid system both in the 
pathogenesis of major depression and anxiety, as well as in the mediation of antidepressant 
response (Martin et al., 2002). In a study conducted in a Caucasian cohort of depressed 
patients receiving various antidepressant medications, the G-allele of a synonymous 
polymorphism (G1359A) of the cannabinoid receptor CB1 (CNR1) gene was shown to confer 
www.intechopen.com
 
Clinical Applications of Pharmacogenetics 
 
174 
a greater risk for resistance to antidepressant treatment, especially in depressed women with 
high comorbid anxiety (Domschke et al., 2008a).  
Galanin (GAL) is a 30-aminoacid estrogen-inducible neuropeptide that derives from 
preprogalanin (PPGAL) (Evans & Shine, 1991). GAL is highly expressed in brain regions 
involved in the regulation of anxiety and depression (Kuteeva et al., 2008). In a recent study 
Unschuld et al. (2010) reported a female-specific association of symptom severity in 
premenopausal depressed women with the rare allele of the PPGAL SNP rs948854. In 
particular, premenopausal depressed women carriers of the G-allele of rs948854, presented 
more severe vegetative but not cognitive depressive symptomatology at discharge and 
worse response to antidepressant medication (Unschuld et al. 2010). According to the 
authors, these results may be related to the existence of several estrogen-response elements 
(ERE) in the promoter region of the PPGAL gene that have been held responsible for the 
estrogenic regulation of GAL expression (Unschuld et al. 2010; Kaplan et al., 1988; Howard et 
al., 1997). 
 
GENE 
GENETIC 
VARIATION 
DRUG RESULT REFERENCE 
CNR1 
G1359A (synonymous; 
Thr453) 
mirtazapine, 
citalopram/escitalopram, 
venlafaxine and 
combinations 
In women the G-allele 
was associated with 
resistance to 
antidepressant treatment 
Domschke  
et al., 2008a 
ACE 
287 bp 
Insertion/deletion 
(I/D) polymorphism 
(intron 16) 
TCAs, or SSRIs or dual-
acting antidepressants 
In women the D-allele 
predicted faster onset of 
different antidepressant 
therapies 
Baghai  
et al., 2004 
PPGAL 
rs948854 
(promoter) 
SSRIs, TCAs or 
mirtazapine  
In women the G-allele 
was associated with 
worse response to 
antidepressant treatment  
Unschuld  
et al., 2010 
Table 3. Sex differences in genetic variants that are associated with other neurobiological 
systems. 
4.4 Pharmacokinetics genes 
Sex differences in antidepressant response have largely been attributed to sex-differentiated 
pharmacokinetic disposition of psychotropic agents. This notion is supported by the fact 
that hormonal fluctuations during the menstrual cycle may affect the pharmacokinetics of 
psychotropic medications (Hildebrandt et al., 2003). Importantly, cytochrome P450 (CYP)-
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3A4, CYP2D6, CYP2C19 and CYP1A2 are important for the metabolism of antidepressant 
drugs (Staddon et al., 2002). Genetic polymorphisms in these CYP genes may account for 
inter-individual pharmacokinetic disposition of psychotropic medications. However, it is 
still not known whether these actually have the same effect in both sexes (Kokras et al., 
2011). Although sex differences in the pharmacokinetics of antidepressants have been 
shown to affect response, the clinical relevance of this sex-differentiated response remains to 
be elucidated (Meibohm et al., 2002; Kokras et al., 2011). 
Notably, sex differences in human CYP-catalyzed drug metabolism are well-documented; 
for instance CYP3A4, the predominant CYP catalyst of oxidative metabolism in human liver, 
is expressed at a higher protein and mRNA levels in women versus men (Waxman & 
Holloway, 2009). Moreover, sex-differentiated genetic markers of CYP3A4 activity and 
expression have recently been reported in human liver microsomes (Schirmer et al., 2007). 
Of note, it is still not clear if sex influences CYP2C19 and CYP2D6 activity in a clinically 
meaningful way in humans (Scandlyn et al., 2008; Borobia et al., 2009). A recent study 
reported that both the CYP2D6 genotype and sex influenced the disposition of mirtazapine 
in a Spanish cohort of healthy volunteers; however, a sex x genotype interaction was not 
detected (Borobia et al., 2009). In support of the aforementioned findings, CYP2C19 and 
CYP2D6 polymorphisms were also shown to affect the disposition of citalopram similarly in 
men and women (Fudio et al. 2010).  
5. Epimyth and future challenges  
The studies reported herein tentatively indicate that variants in genes pertaining to a 
multitude of central processes may affect antidepressant response in a sex-dependent 
fashion. Among these are genes modulating the brain’s monoaminergic systems (e.g. 5-HTT, 
5-HT1A receptor and MAO-A) or even genes related to other fundamental neuromodulatory 
processes (e.g. ACE and GAL). These differences may stem from the complex crosstalk 
between sex hormones and genes modulating the monoaminergic systems by modifying 
gene expression or even epigenetic processes (Petronis, 2001; Damberg, 2005).  
It is widely accepted that there is a substantial inter-individual variation in response to 
antidepressant drugs. Research on the pharmacogenetics of antidepressants aims to identify 
genetic variants implicated in antidepressant response, in order to both serve as predictor of 
the outcome and to decipher their complex mechanism of action. However, as noted in 
recent reviews on this subject-matter, despite the initial enthusiasm, the lack of consistent 
findings regarding genes regulating pharmacokinetic and pharmacodynamic processes has 
been frustrating (Keers & Aitchison, 2011). Notably, it is believed that the few phar-
macogenetic associations that have been replicated explain only a small fraction of 
individual differences in response to antidepressant pharmacotherapies (Uher et al., 2010). 
Still, when novel genetic targets were screened the results appeared to be modest and point 
to the notion that the genetic control of responsiveness to antidepressants is determined by 
multiple genetic loci (Keers & Aitchison, 2011). 
To this direction, genome-wide association studies (GWAS) have revealed novel genetic 
variants and regulatory intergenic sequences that may be very important to the mechanism 
of action of antidepressant drugs. In the Genome-Based Therapeutic Drugs for Depression 
(GENDEP) project, previously unexpected genes related to neurogenetic and immune 
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processes implicated in the pathophysiology of depression, appeared to serve as potent 
predictors of antidepressant response in patients treated for 12 weeks with escitalopram 
(SSRI; N=394) or nortriptyline (TCA; N=312) (Uher et al., 2010). Pharmacogenomic analyses 
revealed a significant association between the uronyl 2-sulphotransferase (UST) gene and 
response to nortriptyline. On the other hand, response to escitalopram was predicted by a 
marker in the gene encoding interleukin-11 (IL-11), with this being further supported by a 
less robust association in the IL-6 gene (Uher et al., 2010). In another GWAS study, Garriock 
et al. (2010) used the STAR*D sample in order to determine which DNA variations 
influenced response to citalopram treatment and also implicated novel genes in the 
mechanism of action of SSRIs (Garriock et al., 2010). Despite the significance of these studies 
in the field, the role of sex was not determined.  
Overall, despite the promising advances in this field, pharmacogenetics-driven, 
personalized antidepressant pharmacotherapies are still far from being introduced into the 
clinical practice (Drago et al., 2009). Although it is still early for firm conclusions, the 
currently available evidence seems to suggest that an intriguing genetic x sex interplay may 
be associated with the differential responsiveness that the two sexes exhibit upon 
antidepressant treatment. Therefore, a profound analysis of the role of sex in the 
pharmacogenetics of depression is considered imperative in order for the clinical 
significance of this interaction to be determined.  
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